Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

I never imagined that coming off a medication could feel like stepping off a cliff. But here I am, bracing for the freefall.

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.

Market Overview: The Weight Management Supplements Market is expected to grow at a CAGR of 12.4% from 2024 to 2031. This expansion is being driven by rising obesity rates, increased awareness of ...

For decades, meaningful weight loss has been an elusive goal for millions of Britons. Diet plans come and go, exercise regimens start with enthusiasm and fade with time, and the statistics remain grim ...

GLP-1 weight-loss drugs like Ozempic and Wegovy may help reduce alcohol cravings and heavy drinking, offering promising potential in treating alcohol use disorder alongside managing obesity and ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.